TABLE 1.
SAD study summary of baseline subject characteristics
| SAD demographics | |||||
|---|---|---|---|---|---|
| LTI‐291 or placebo | 3 mg LTI‐291 | 10 mg LTI‐291 | 30 mg LTI‐291 | 90 mg LTI‐291 | Placebo |
| n | 8 | 8 | 8 | 8 | 8 |
| Male/female | 6/2 | 4/4 | 7/1 | 8/0 | 6/2 |
| Age (years), mean (range) | 29.5 (18–56) | 49.5 (22–63) | 27.5 (18–56) | 38.1 (23–64) | 46.0 (30–63) |
| BMI (kg/m2), mean (range) | 23.8 (19.7–27.3) | 23.9 (18.9–28.3) | 23.7 (19–28.6) | 24.9 (19.7–29.8) | 24.2 (22.3–27.6) |
| Race | |||||
| Caucasian | 8 | 6 | 7 | 8 | 7 |
| Black | 0 | 1 | 1 | 0 | 1 |
| Asian | 0 | 1 | 0 | 0 | 0 |
| GBA1 wild type/mutation | 8/0 | 8/0 | 8/0 | 5/3 | 8/0 |